Aligos Therapeutics, Inc. (ALGS) Overview
- 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.14; Beat / miss (m).
- 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -2.21; Beat / miss (m).
- 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -3.04; Beat / miss (m).
- 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -1.53; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $4.13
- Previous close
- $5.62
- Change
- -$1.50
- Change (%)
- -26.60%
- Close date
- 2026-11-06
- Previous close date
- 2026-09-29
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- ALGS
- -39.70%
- S&P 500
- (m)
1 year
- ALGS
- -41.58%
- S&P 500
- (m)
3 years
- ALGS
- -69.90%
- S&P 500
- (m)
5 years
- ALGS
- -98.52%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
30 Jun 2026 ○ Estimate (m) ● Actual -0.14
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Apr 2026 | 30 Jun 2026 | (m) | -0.14 | (m) | (m) |
| 1 Jan 2026 | 31 Mar 2026 | (m) | -2.21 | (m) | (m) |
| 1 Jul 2025 | 30 Sept 2025 | (m) | -3.04 | (m) | (m) |
| 1 Apr 2025 | 30 Jun 2025 | (m) | -1.53 | (m) | (m) |
| 1 Jan 2025 | 31 Mar 2025 | (m) | -2.11 | (m) | (m) |
31 Dec 2025 ○ Estimate (m) ● Actual -2.45
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2025 | 31 Dec 2025 | (m) | -2.45 | (m) | (m) |
| 1 Jan 2024 | 31 Dec 2024 | (m) | -20.94 | (m) | (m) |
| 1 Jan 2023 | 31 Dec 2023 | (m) | -34.20 | (m) | (m) |
| 1 Jan 2022 | 31 Dec 2022 | (m) | -2.25 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
30 Jun 2026 ■ Revenue 0.00M ■ Earnings -1.50M — Profit margin (m)
31 Dec 2025 ■ Revenue 2.19M ■ Earnings -24.19M — Profit margin -1106.72%
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $4.13 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning ALGS
View more →(m)
Statistics
View more →Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $-75.96M
- Operating margin · 12 months
- -2112.14%
- Profit margin
- -2031.07%
- Return on assets · 12 month
- -75.57%
- Named executive and board stock awards · latest fiscal year
- (m)
- Index membership
- (m)
- Employees
- (m)
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 48.85K
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- -1.06%*
- Total return · month
- -18.67%*
- Total return · quarter
- 3.50%*
- Total return · half year
- -15.62%*
- Total return · year to date
- -39.70%*
- Total return · 1 year
- -41.58%*
- Total return · 3 years
- -69.90%*
- Total return · 5 years
- -98.52%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- R&D / revenue · 12 months
- 2363.02%
- Revenue · 12 month
- $3.74M
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Operating cash flow · 12 months
- $-94.17M
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- (m)
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
Aligos Therapeutics, Inc. Overview
View more →(m)
(m)
- SEC CIK
- 1799448
- Industry (SIC)
- 2836 Biological Products, (No Diagnostic Substances)
- Country of operation
- United States
- Business address
- ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, California, 94080, United States
- Fiscal year end
- 1231
- Phone
- (800) 466-6059
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |